The Centers for Medicare and Medicaid Services (CMS) has issued a permanent billing code (B4105) to Alcresta Therapeutics’…
Articles by Vijaya Iyer, PhD
Vertex Pharmaceuticals has announced its intention to submit an application to the Scottish Medicines Consortium (SMC) to review the…
Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented at the 2018…
Galapagos and AbbVie agreed that AbbVie will now have full control of the cystic fibrosis (CF) drug discovery portfolio…
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might…
Antibiotics lessen the diversity of microbes in the lungs of cystic fibrosis (CF) patients, and make these people more…
Blocking superoxide dismutase, the enzyme that responds to stress, in Pseudomonas aeruginosa bacteria improves antibiotics’ efficacy, a Canadian study reported.
Vertex Pharmaceuticals has completed enrollment for two Phase 3 studies testing the triple combination therapy of its new CFTR corrector…
Vertex Pharmaceuticals and Genomics announced a three-year collaboration to better understand genetic variations and their effect on clinical outcomes…
In addition to mutations in the CFTR gene, cystic fibrosis (CF) patients with pancreatitis also have a high…